Viridian Therapeutics Past Earnings Performance
Past criteria checks 0/6
Viridian Therapeutics's earnings have been declining at an average annual rate of -35.2%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 33.7% per year.
Key information
-35.2%
Earnings growth rate
31.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -33.7% |
Return on equity | -37.4% |
Net Margin | -75,737.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Viridian Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -218 | 88 | 0 |
31 Dec 23 | 0 | -238 | 95 | 0 |
30 Sep 23 | 0 | -217 | 72 | 0 |
30 Jun 23 | 1 | -198 | 60 | 0 |
31 Mar 23 | 2 | -172 | 49 | 0 |
31 Dec 22 | 2 | -130 | 35 | 0 |
30 Sep 22 | 2 | -113 | 32 | 0 |
30 Jun 22 | 1 | -98 | 30 | 0 |
31 Mar 22 | 2 | -87 | 28 | 0 |
31 Dec 21 | 3 | -79 | 26 | 0 |
30 Sep 21 | 3 | -141 | 24 | 0 |
30 Jun 21 | 3 | -133 | 21 | 0 |
31 Mar 21 | 2 | -121 | 17 | 0 |
31 Dec 20 | 1 | -111 | 13 | 0 |
30 Sep 20 | 2 | -30 | 10 | 0 |
30 Jun 20 | 3 | -36 | 11 | 0 |
31 Mar 20 | 5 | -38 | 11 | 0 |
31 Dec 19 | 4 | -42 | 12 | 0 |
30 Sep 19 | 4 | -42 | 12 | 0 |
30 Jun 19 | 4 | -40 | 12 | 0 |
31 Mar 19 | 4 | -40 | 11 | 0 |
31 Dec 18 | 8 | -33 | 11 | 0 |
30 Sep 18 | 9 | -29 | 11 | 0 |
30 Jun 18 | 10 | -26 | 11 | 0 |
31 Mar 18 | 8 | -24 | 11 | 0 |
31 Dec 17 | 4 | -27 | 11 | 0 |
30 Sep 17 | 3 | -26 | 11 | 0 |
30 Jun 17 | 3 | -24 | 10 | 0 |
31 Mar 17 | 3 | -21 | 9 | 0 |
31 Dec 16 | 3 | -17 | 7 | 0 |
30 Sep 16 | 4 | -17 | 5 | 0 |
31 Dec 15 | 5 | -16 | 4 | 0 |
31 Dec 14 | 8 | -6 | 4 | 0 |
Quality Earnings: 1S1 is currently unprofitable.
Growing Profit Margin: 1S1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1S1 is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare 1S1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1S1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 1S1 has a negative Return on Equity (-37.44%), as it is currently unprofitable.